Clinical Trial Update: Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Status update indicating that the Phase 2 trial of EGFR-status based gefitinib neoadjuvant therapy for non-small cell lung cancer has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: SUSPENDED